Europe's cancer diagnostic testing market is poised for rapid growth in the next five years, largely driven by expected tech breakthroughs creating lots of opportunities for genetic risk assessment, detection of specific tumors, as well as for the monitoring of biological response to cancer treatment. The increase in geriatric population will further add to the rising demand for malignancy assays, thus contributing to the fast-paced market development.
Tumor marker testing represents a key opportunity for DNA probes in general and for the application of molecular pathology techniques specifically. Numerous oncogenes have been identified, including p53, C-erB2, and BRCA1. The latter is implicated in the development of 50% of all inherited breast cancers, and also associated with elevated risk for prostate and other cancers. Within the next few years, it could become prevalent practice in the clinical laboratory settings to conduct a complete molecular pathology analysis of all excised breast tumors to evaluate metastatic potential and help guide adjuvant drug treatment. As additional oncogenes are discovered related to diseases such as prostate and colorectal cancer, such kind of testing is likely to expand.
New research study "Cancer Testing in Europe: Market Segment Forecasts and Supplier Shares"created by Venture Planning Group (VPG) provides an in-depth investigation of business opportunities emerging in the cancer diagnostics market during the next five years in the key European countries, such as France, Germany, Italy, Spain, and the United Kingdom.
The report provides an overview of current and emerging tests; analysis of potential applications of various diagnostic technologies; forecasting of sales of major tumor markers by country and market segment; profiles of the leading market players and would-be entrants; besides suggesting alternative business expansion strategies for suppliers.
Report Details:
Title: Cancer Testing in Europe: Market Segment Forecasts and Supplier Shares
Published: May, 2013
Pages: 820
Price: US$ 19,700.00
http://marketpublishers.com/report/diagnostics-diseases/cancer/cancer-testing-in-europe-market-segment-forecasts-n-supplier-shares.html
Report Contents:
INTRODUCTION
WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Cancer Statistics and Etiology
1. Brest Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
More new studies by VPG can be found at http://marketpublishers.com/members/vpg/info.html
Contacts:
The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com
